Letter: Fibrinolytic activity and treatment of diabetes.
D001645:Biguanides / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004032:Diet; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D013453:Sulfonylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use
D001645:Biguanides; D007328:Insulin; D013453:Sulfonylurea Compounds